← Back

Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutics for cancer patients. Its pipeline includes PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway being developed for endometrial and breast cancer, and Solnerstotug, a monoclonal antibody in Phase 1/2 targeting the immune checkpoint VISTA for solid tumors. Early-stage programs include the monoclonal antibodies SNS-102 and SNS-103 for solid tumors, and SNS-201, a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc., changed its name to Faeth Therapeutics, Inc. in June 2026, was incorporated in 1999, and is headquartered in Rockville, Maryland.

Price · split & dividend adjusted
News & notes moving FTH
Biotech & Genomic Medicine▲

Biotech Stocks AMWL, CUE, ICCC, SRRK, FTH Hit 52-Week Highs

Several biotech stocks reached 52-week highs on July 10, 2026, driven by regulatory updates and quarterly results. American Well Corporation hit $10.16, closing at $9.91, after a Nature report validated its SilverCloud platform and it facilitated a DarioHealth insurer agreement, though full-year 2026 revenue is expected at $195 million to $205 million, below 2025's $249.3 million. Cue Biopharma reached $45.50 and announced a roughly $50 million private placement, while advancing CUE-221 in a Phase 2 allergy study and planning an IND for CUE-401. ImmuCell climbed to $11.59 after reporting unaudited second-quarter sales of $7.2 million, an 11.5% year-over-year increase, with $4.9 million from Tri-Shield First Defense. Scholar Rock hit $58.49, up 3.33%, as its BLA for Apitegromab in SMA is under FDA review with a decision expected by September 30, 2026. Faeth Therapeutics touched $36.89, advancing the PIKTOR combination therapy in a Phase 1/2 breast cancer trial with interim data due in 2027 and a Phase 2 endometrial cancer trial with topline data expected in the second half of 2026.
CUE ▲ICCC ▲SRRK ▲AMWL FTH ▲
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Regulation
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Capital
Biotech & Genomic Medicine › Oncology Therapeutics Capital
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO Capital
CUE · Capital · Positive Announced roughly $50 million private placement and advanced CUE-221 in Phase 2 allergy study.
ICCC · Demand · Positive Reported unaudited Q2 sales of $7.2 million, an 11.5% YoY increase, with $4.9 million from Tri-Shield First Defense.
SRRK · Regulation · Positive BLA for Apitegromab in SMA under FDA review with decision expected by September 30, 2026.
AMWL · Demand · Neutral Nature report validated SilverCloud platform and facilitated DarioHealth insurer agreement, but full-year 2026 revenue expected below 2025.
FTH · Technology · Positive Advancing PIKTOR combination therapy in Phase 1/2 breast cancer trial with interim data due in 2027 and Phase 2 endometrial cancer trial with topline data expected H2 2026.
Read original ↗
RTTNews·83dRead more →
Biotech & Genomic Medicine

uniQure Leads Biotech Gainers After FDA Softens Stance on Gene Therapy

uniQure led a group of biotech gainers on Wednesday after the FDA softened its stance on the company’s investigational gene therapy AMT-130 for Huntington’s disease. The agency now considers the 3-year analysis from the Phase I/II study acceptable as the primary basis for a Biologics License Application for accelerated approval, reversing its earlier recommendation for a prospective, randomized, double-blind, sham-surgery-controlled study. uniQure intends to submit the BLA in the third quarter of 2026, and its shares closed at $48.16, up 78.44%. Other notable movers included Elicio Therapeutics, which rose 70.65% after reporting that three advanced pancreatic cancer patients in its Phase 2 AMPLIFY-7P study achieved complete responses following treatment with its vaccine ELI-002 7P and subsequent checkpoint inhibitor therapy. Lunai Bioworks gained 40.06% after its CEO outlined developments including a first revenue-generating U.S. government defense contract and the formation of the Pathfinder Consortium. ClearPoint Neuro climbed 26.01% on spillover optimism related to uniQure’s AMT-130, which is administered using ClearPoint’s navigation system. Polyrizon added 15.55% after the publication of a U.S. patent application for its nasal drug delivery technology, and Faeth Therapeutics rose 14.59% as it anticipates topline data from a Phase 2 trial of its lead candidate PIKTOR in advanced endometrial cancer in the second half of 2026.
ELTX ▲LNAI ▲PLRZ ▲QURE ▲CLPT ▲FTH
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › Gene & Cell Editing ▲Regulation
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
ELTX · Technology · Positive Three advanced pancreatic cancer patients achieved complete responses in Phase 2 study of ELI-002 7P.
LNAI · Demand · Positive CEO outlined first revenue-generating U.S. government defense contract and Pathfinder Consortium formation.
PLRZ · Technology · Positive U.S. patent application published for nasal drug delivery technology.
QURE · Regulation · Positive FDA softened stance on AMT-130, allowing accelerated approval pathway.
CLPT · Demand · Positive ClearPoint's navigation system used for uniQure's AMT-130 administration, benefiting from spillover optimism.
FTH · Technology · Neutral Mentioned as anticipating topline data from a Phase 2 trial in 2026, but no results or regulatory news in this article.
Read original ↗
RTTNews·108dRead more →
© 2026 MarketDXAsset